Introduction
Rheumatic heart disease (RHD) is an autoimmune progressive destructive valvular disorder that occurs as a sequel of acute rheumatic fever in genetically predisposed subjects. Molecular mimicry between tissue proteins and streptococcal antigens like M protein (the major component and most virulent factor of streptococcal cell surface) leads to autoimmunity.
the other hand, in a preliminary observational study, we have reported that T regulatory cells (Tregs), which inhibit the autoreactive effector CD4cells and protect against tissue injury, are significantly decreased in patients of RHD. 9 One of the major limitations of our study was that we defined Tregs as CD4+CD25+ cells, but the surface marker CD25 is also expressed by activated nonregulatory T cells. 10 In current literature, Tregs are defined as CD4CD25 positive cells with increased intracellular concentration of the transcription factor Fox P3.
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As Fox P3 is intracellular, it cannot be used to separate human Treg cells for functional studies or to assess in vivo expansion for cellular therapy, thereby limiting its use in human setting. Recently, a new surface marker CD 127 (interleukin 7 receptor) has been reported, which can be used in lieu of Foxp3 to define Tregs (CD127 expression varying inversely with FoxP3 concentration) and differentiate them reliably from nonregulatory T cells. [12] [13] [14] Accordingly, Koreth et al. 15 defined CD4+ cells with moderate to high expression of CD25 and low expression of CD127 (as these cells have high intracellular Foxp3) as Tregs, while CD4 cells with low expression of CD25 and medium to high expression of CD127 as T conventional cells (as these cells have low intracellular Fox P3).* As there have been no studies using these markers in patients of RHD, we decided to use all the four markers, CD4, CD25, CD127, and Fox P3, to reliably differentiate Treg from Tcon cells and assess their levels in patients of RHD. In our study, Tregs were defined as cells, which were CD4 +CD25 Hence, to overcome the limitation of our previous study, we undertook this study to reevaluate the level of circulating Tregs cells in patients of RHD using more specific markers. Secondly, in our preliminary study, circulating Tregs were lower to a greater extent in patients with extensive disease (multivalvular involvement) compared to limited disease (univalvular involvement). 9 The secondary aim of our present study was to assess the level of circulating Treg, in patients with univalvular (limited) and multivalvular (extensive) disease.
Materials and methods
A total of 105 adult subjects were enrolled in the study, which was cross sectional in design. Patients with echocardiographic evidence of RHD were further subdivided according to the extent of left-sided valvular involvement. 35 patients with echocardiographic evidence of significant mitral valve disease only (moderate to severe mitral stenosis and/or moderate to severe mitral regurgitation) were enrolled in 'univalvular' group, while 35 patients with significant involvement (moderate to severe) of both mitral and aortic valves were enrolled in the 'multivalvular' group. The control group comprised of 35 healthy volunteers. Patients with autoimmune, hematological, or rheumatologic disorders, diabetes mellitus, vasculitis, malignancies, acute or chronic systemic and/or local infection, infective endocarditis, history of rheumatic fever within 2 years, cardiomyopathies, left ventricular ejection fraction (LVEF) <50%, atrial fibrillation, coronary artery disease; pulmonary, renal, and hepatic disorders were excluded.
The study was approved by the institutional ethics committee at the authors' institution, and all subjects provided their written informed consent voluntarily to participate in the study. None of the subjects enrolled in the study had declined to participate in the study and gave consent to look at health records both in respect of the current study and any further research that may be conducted in relation to it. The subjects also agreed that they do not have any objection to the use of any data or results that arise from this study provided it is used, only for scientific purpose.
Study procedures
Demographic variables including age and sex were recorded. All patients underwent detailed clinical evaluation to assess their New York Heart Association (NYHA) functional class, severity and extent of valvular disease and exclusion of concomitant conditions like acute rheumatic fever, infective endocarditis, systemic infections, and autoimmune diseases.
Electrocardiogram was evaluated to detect rhythm abnormalities and chamber enlargements. Transthoracic echocardiography (Philips, IE33) was performed in order to evaluate extent and severity of valvular involvement. The extent and severity of disease in mitral and aortic valves were evaluated as already described in our previous study. 9 All echocardiograms were performed by the same operator to avoid interobserver variability. Baseline laboratory tests, hemogram, renal function tests, and liver function tests were performed in all patients. Total leukocyte count (TLC) and lymphocyte count were determined by automatic analyzer (Sysmex, XT2000i Singapore). The erythrocyte sedimentation rate (ESR; Westergren method) and C-reactive protein (CRP) levels (CRP-Turbilatex, Spinreact, S.A.U. Spain) were estimated in all cases. Special laboratory tests (antinuclear antibody, rheumatoid arthritis factor) were done in selected patients if clinically indicated to exclude other autoimmune diseases.
2.2.
Flow cytometry 5 ml of peripheral venous blood was obtained from patients with RHD and normal healthy volunteers in EDTA tubes. The blood samples were transported to the laboratory (ensuring sterility) at room temperature for isolation of the peripheral blood mononuclear cells (PBMCs). Flow cytometry analysis was done in a blinded manner. PBMCs were isolated by using commercially available lysing solution (FACS lyse solution, BD Biosciences) according to manufacturer's recommendations. The PBMCs were then washed twice with phosphate buffered saline (PBS) (pH 7.4). The isolated PBMCs were incubated with following conjugated antihuman monoclonal antibodies. CD4 phycoerythrin (PE), CD25 piperidine chlorophyll protein (PerCP), and 127 allophycocyanin (APC) for cell surface markers according to the manufacturer's instructions (Serotec, Oxford, UK). Stained PBMCs were processed with fixation buffer and permeabilizing buffer (Ebioscience Inc., USA) and were incubated with fluorescein isothiocyanate (FITC) conjugated antiFoxp3 (Ebioscience Inc., USA). Cells were then fixed in 500 ml of 2% paraformaldehyde in 0.1 M PBS (phosphate buffer solution) and were kept at room temperature in dark for 30 min. After incubation, cells were washed twice in staining buffer and pelleted by centrifugation to resuspend again in PBS for acquisition and analysis on Flow Cytometer. A FACS Calibur TM Flow Cytometer (Becton Dickinson, Mountain View, USA) equipped with a 15 mW argon ion laser and filter settings for FITC, PE, PerCP, and APC were used in this study. The Flow Cytometer was calibrated and compensated using CaliBRITE TM beads using FACSCOMP software according to the manufacturer's recommendations. Total 10,000 events were acquired for each sample. The compensation standard used was lymphocyte stained with strongly positive single-color monoclonal antibodies for surface markers, e.g., CD4 or CD25 i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 3 4 2 -3 4 8 or CD127 and intracellular Foxp3 in separate tubes. For each of the fluorochromes FITC, PE PerCP and APC, appropriate fluorescence minus one (FMO) and relevant isotype controls (Ebiosciences) were used to determine the nonspecific binding of monoclonal antibodies under study. An initial standardization of the technique was done on samples from control subjects. As a result of the differences, in the cell size and granularity, light scattering separates the blood cells into three major populations: lymphocytes, monocytes, and granulocytes. For each analysis, dot plot graphs of forward scatter versus side scatter were drawn, and a lymphocyte region was defined by placing a tight gate (R6) according to cell size and complexity, where debris and monocytes were excluded (Fig. 1a) . CD4 T cells were gated by their low side scattered characteristics and also by the high expression of CD4+ (R7), thus excluding CD4 low monocytes and dead cells (Fig. 1b) (Fig. 1a-e ).
Statistical analysis
Results have been expressed as mean AE SD for normally distributed data and as median with inter-quartile range for non-normal distributed data and frequencies as percentages. 
Results
The demographic profile and baseline characteristics of patients and control are listed in Table 1 . There was no significant difference in age or sex ratio between patients of RHD versus controls or between the univalvular and multivalvular group. In the univalvular group, 22 (71%) patients had severe mitral stenosis and 7 (23%) had moderate mitral stenosis. Mean mitral valve area by planimetry was 0.82 AE 0.15 cm 2 and
Wilkins score was 6.8 AE 1.4. 25 (71%) patients in this study group had associated mitral regurgitation, of which 12 patients (34%) had mild, 7 (20%) had moderate and 6 (17%) had severe mitral regurgitation. Mild aortic regurgitation was present in 8 (23%) patients. Secondary tricuspid and pulmonary regurgitation due to pulmonary artery hypertension were present in 28 (80%) and 5 (14%) patients, respectively (Table 2 ). In the multivalvular group (n = 35), all patients had multivalvular involvement in the form of either moderate or severe mitral and aortic valve disease (Table 3) . In this group, secondary tricuspid and pulmonary regurgitation was present in 33 (94%) and 6 (17%) of patients, respectively ( Table 3) .
The ESR and CRP levels were within normal limits in both the univalvular and multivalvular group with no significant Values are represented in mean AE SD, median [Inter quartile range], and n (%). NS, non-significant; RF, rheumatic fever; RHD, rheumatic heart disease. NYHA, New York heart Association; M:F, male:female.
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 3 4 2 -3 4 8 difference between the two groups ( Table 1) . While the total cell count was not statistically significant between patients and controls (Table 4) , the absolute lymphocyte count (per mm 3 ) was significantly lower in patients of RHD compared to controls ( Table 4 ). The percentage of Tregs in CD4 lymphocytes was significantly lower in patients of RHD compared to controls ( p = 0.001, Table 4 ).
The absolute lymphocyte count (per mm There was no significant difference in the percentage of Tcon cells in patients with RHD compared to controls ( p = 0.94). Similarly no difference in Tcon cells compared to controls was seen either in univalvular ( p = 0.84) or multivalvular groups ( p = 1.0), or between univalvular and multivalvular groups ( p = 0.34) ( Table 5) .
There was no correlation of ESR or CRP with circulating Treg cells or Tcon cells in our study.
Discussion
The aim of our present study was to assess the level of circulating Tregs, in adult patients of chronic RHD and also assess the same in patients with extensive disease compared to limited disease. There are no data available in world literature regarding the frequency of circulating Tregs cells in patients of RHD using the markers we have used to define regulatory cells to compare i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 3 4 2 -3 4 8
our present results. But like our previous study, the level of circulating Tregs was significantly lower in our overall study population of RHD compared to controls. On subgroup analysis, though the frequency of circulating Tregs was lower than the control group, in both the univalvular and multivalvular group, it achieved statistical significance only in patients with multivalvular disease. But apart from quantitative deficiency, the circulating Tregs may also have been made dysfunctional by the streptococcal antigen as has been shown by in vitro studies 16 
24-29
Selective expansion of Tregs by IL-2 injection (thus restoring the imbalance between Treg and Effector cells) has been shown to arrest and even reverse the tissue damage in various organs in patients of hepatitis C virus induced vasculitis 30 and graft versus host disease 14 Our study, using the latest markers to define Tregs, has conclusively shown the presence of Treg cell deficiency in patients of RHD. Hence, in future, studies are needed to see whether correction of Treg cell deficiency can attenuate or arrest the progress of autoimmune valve damage in RHD. This approach may become the future therapeutic modality for patients of RHD.
Limitation of the study
We could not assess the suppressive function of the Tregs due to lack of facilities. But from our study results, we feel that functional deficiency of the Tregs was primarily responsible for mediating damage in patients with limited disease. Hence, studies should be conducted to assess the functional deficiency of Tregs in patients of RHD.
Conclusion
There is significant deficiency of circulating Tregs in patients of chronic RHD and both qualitative (functional) and quantitative deficiency of the Tregs are responsible for autoimmune damage to the valves by autoreactive T cells.
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